share_log

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $60 Price Target

Benzinga ·  Oct 9, 2023 06:17

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $60 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment